For years now Big Pharma's deep pockets have provided the big bucks needed to drive multibillion-dollar deals in biopharma--and quite a few of the smaller ones as well.
In a holiday present to people with Parkinson's disease and restless legs syndrome, the Japanese Ministry of Health, Labor and Welfare approved the transdermal patch Neupro in Japan on Dec. 25 for these two indications.
Catalent has signed a deal to provide biosimilar cell lines to Japan's UMN Pharma, a development and manufacturing agreement designed to jump-start the CMO's presence on the Asian market.
Japanese conglomerate Omron has pulled the trigger on a major expansion of its med tech business in India.
Thoratec's push to keep sales surging for its HeartMate II pump will move to Japan, now that regulators have signed off on the device. Plans call for a commercial launch to begin at the end of the 2013 first quarter.
Sorin Group scored a big win in Japan--regulatory approval for its Mitroflow aortic pericardial heart valve.
Orexo's Japanese partner Kyowa Hakko has resubmitted Abstral, a sublingual fentanyl tablet that delivers the opioid drug under the tongue for the treatment of breakthrough cancer pain, for marketing approval in Japan.
Novartis has submitted the once-daily inhaled combination drug QVA149 for approval in Japan for the maintenance treatment of COPD in adults.
Zoll Medical ($ZOLL) is expanding into Japan with a new subsidiary expected to beef up sales of the company's external defibrillators, monitoring equipment and other medical devices.
Generic drugmaker Mylan is boosting its manufacturing capacity in oncology drugs by acquiring a 4-year-old, FDA-approved plant in India from SMS Pharmaceuticals for $32.5 million.